TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
AUSTIN, TX—Daniel Rabinowitz, the Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), recently sold 1,993 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The sale, executed on April 28, 2025, amounted to a total value of approximately $303,299, with each share sold at a price of $152.18. The transaction comes as Natera, currently valued at $20.55 billion, has delivered a remarkable 60% return over the past year, according to InvestingPro data.
The transaction was conducted to meet tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). This sale was carried out under a pre-arranged trading plan, compliant with Rule 10b5-1(c) under the Exchange Act. Following the transaction, Rabinowitz retains ownership of 223,674 shares in the company. With Natera’s next earnings report due on May 7 and the company maintaining a GREAT financial health score, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports.
In other recent news, Natera reported its fourth-quarter 2024 earnings, exceeding Wall Street expectations with a revenue of $476 million, a 53% increase year-over-year, and a narrower-than-anticipated loss per share of -$0.41. Analysts from TD Cowen and Canaccord Genuity have expressed confidence in Natera’s future, maintaining Buy ratings and setting a $195 price target, citing strong sales projections and robust growth levers for 2025. Additionally, Natera has launched the Signatera Genome assay nationwide, a test designed to detect circulating tumor DNA for cancer management, which has been supported by clinical studies and Medicare coverage for multiple cancer types. The company has also initiated the HEROES clinical trial in France, exploring the potential for therapy de-escalation in metastatic HER2+ breast cancer patients, using the Signatera test to guide treatment decisions. These developments reflect Natera’s continued focus on expanding its genetic testing capabilities, supported by ongoing clinical trials and strategic investments in research and development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.